Individualizing Management of Endometriosis Pain: Current Evidence, Potential New Strategies, and Ongoing Research

Anita L. Nelson, MD Professor Emeritus, Obstetrics & Gynecology David Geffen School of Medicine at UCLA Clinical Professor, Obstetrics & Gynecology University Southern California Professor and Chair, Obstetrics & Gynecology Western University of Health Sciences

omnia EDUCATION

Conflict of Interest Disclosure Anita L. Nelson, MD

Grants/ Research	 Mylan Pharmaceuticals, Myovant Sciences, Organon/Merck & Co., Sagami Rubber Industries, Sebela Pharmaceuticals Agile Therapeutics, Bayer HealthCare, Mayne Pharma, Myovant Sciences, Organon/Merck & Co., TherapeuticsMD 				
Honoraria/ Speakers Bureau					
Consultant/ Advisory Board	Agile Therapeutics, Bayer HealthCare, Mayne Pharma, Pfizer, TherapeuticsMD				

omnia[™] EDUCATION

Learning Objectives

At the end of this presentation, the participant will be able to

- Identify clinical practices that support the accurate and timely diagnosis of endometriosis
- Assess benefits and challenges of various medical therapies for initial and ongoing care of women with endometriosis
- Evaluate recent clinical trial and real-world data about the medical management of endometriosis



Endometriosis

- Endometriosis is a chronic inflammatory disorder that substantially reduces women's quality of life¹
- Technically defined as ectopic presence of glandular and stromal endometrial tissue with hemosiderin-laden macrophages
- Molecular differences exist between those endometriotic implants and normal endometrium¹
- Influenced by genetic, environmental, epidemiologic, inflammatory, immunologic, and angiogenic factors²
 - Even microbiome implicated³



Epidemiology

- Recent estimates: endometriosis affects 10% of reproductive-age women¹
 - \sim 190 million women worldwide
- Prevalence varies among different groups¹
 - 2%-11% asymptomatic women
 - 21%-47% women with subfertility
 - 71%-87% women with chronic pelvic pain
- Prevalence in young women is underappreciated²
- 75% of those unresponsive to medical therapy for pelvic pain have endometriosis³

omnia™ EDUCATION

Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256.
 Falcone T, et al. Obstet Gynecol. 2018;131(3):557-571.
 Ballweg ML. J Pediatr Adolesc Gynecol. 2003;16(3 Suppl):S21-S26.

Clinical Presentation of Endometriosis

- Average age of diagnosis 28 years¹
 - 52% diagnosed between ages 18-29 years
- 86% symptomatic for 7-8 years on average before diagnosis made¹
 - Symptoms: dysmenorrhea (73%); pelvic pain (57%); dyspareunia (43%)²
- Women with endometriosis
 - 2.7 times more likely to have severe symptoms of other pains³
 - More likely to have co-existing conditions



Falcone T, et al. Obstet Gynecol. 2018;131(3):557-571.
 Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256.
 Fuldeore M, et al. Gynecol Obstet Invest. 2017;82(5):453-461.

Risk Factors for Endometriosis

- Family history¹
 - RR 7- to 10-fold higher if first-degree relative affected
- Early menarche¹
- Frequent or heavy menses¹
- Nulliparity¹
- Low BMI, alcohol use, autoimmune disease²
- Common genetic variants being identified²
- Uterine fibroids³



Falcone T, et al. Obstet Gynecol. 2018;131(3):557-571.
 Shigesi N, et al. Hum Reprod Update. 2019;25(4):486-503.
 Lin KY, et al. PLoS One. 2021;16(8):e0256772.

Special Case: Endometriosis in Teens

- Signs and symptoms differ from adults¹
 - 90.6% acyclic pain +/- cyclic (62.5%)
 - >50% GI symptoms, GU symptoms²
- Migraines more prevalent in teens with endometriosis vs other teens³
- 1/3 of teens said dysmenorrhea and pain started before age 15⁴



Laufer MR, et al. J Pediatr Adolesc Gynecol. 1997;10(4):199-202.
 Dun EC, et al. JSLS. 2015;19(2):e2015.00019.
 Miller JA, et al. Fertil Steril. 2018;109(4):685-690.
 Ballweg ML. J Pediatr Adolesc Gynecol. 2003;16(3 Suppl):S21-S26.
 ACOG Committee Opinion No. 760. Obstet Gynecol. 2018;132(6):e249-e258.

Endometriosis Impacts

- Two important impacts: pain and infertility¹
- Costs similar in magnitude to costs for type 2 DM, Crohn's disease, rheumatoid arthritis²
- The cost of care to manage the spectrum of symptoms is much greater
 - Affects physical, mental, sexual, and social well-being as well as productivity³
 - Societal burden of endometriosis: \$49 billion per year if indirect costs and productivity losses are included⁴
- Pain is intense: opiate use 3x higher than controls³ and used by 2/3⁵



Patel BG, et al. Best Pract Res Clin Obstet Gynaecol. 2018;50:50-60.
 Simoens D, et al. Hum Reprod. 2012;27(5):1292-1299.
 Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256.
 Falcone T, et al. Obstet Gynecol. 2018;131(3):557-571.

5. As-Sanie S, et al. J Minim Invasive Gynecol. 2021;28(2):297-306.e2.

Endometriosis-Related Symptoms

- Chronic pelvic pain (acyclic)
- Dysmenorrhea
- Deep dyspareunia
- Dysuria

- Dysphasia
- Fatigue
- Infertility
- Somatosensory amplification

Significant decrease in quality of life



Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256. Levin G, et al. J Gynecol Obstet Hum Reprod. 2020;49(7):101744.

Manifestations of Endometriosis

- Superficial peritoneal lesions
 - Various colors (clear, yellow, red, brown, blue-black)
 - Various locations
- Ovarian endometrioma

omnia

FDUCATION

- Deep infiltrative endometriosis
 - Vascularization of lesions
 - Innervation of lesions
 - Scarring or adhesions within the pelvic cavity
 - Extra-pelvic lesions

Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256.

Pathophysiology Then and Now

- Classical Sampson's theory
 - Retrograde menstruation
 - Coelomic metaplasia

omnia[®]

FDUCATION

 Lymphatic and vascular metastasis

- Newer, much more complex process envisioned
 - Immune factors
 - Hormonal factors
 - Inflammatory response
 - Heritable factors

Zondervan KT, et al. N Engl J Med. 2020;382(13):1244-1256.

Endometriosis as a Public Health Problem

- Major impact on QOL and economic cost
- Diagnosis now based on structural process of patient interview, clinical examination, and imaging
- Need to rethink old approach with immediate surgery
 - Consider patient's "endometriosis life"
- Medical management is first-line therapeutic option for women with pelvic pain and no desire for immediate pregnancy
- Modern endometriosis care should be individualized with patient-centered, multimodal, and interdisciplinary integrated approach

omnia

FDUCATION

Challenges in Making the Diagnosis

- Patient hesitancy to bring up due to past disappointments, stigma
 - Diagnosis missed, treatment incomplete
- Varied physical manifestations, superficial lesions, deep infiltrative disease, endometrioma, severe dysmenorrhea
- Nonspecific or no symptoms, dyspareunia, chronic pelvic pain, infertility, dysphasia...
- Past reliance on surgical diagnosis
- Lack of public (and professional) awareness of the problem



Differential Diagnoses for Endometriosis (Level A)

- Adenomyosis
- Interstitial cystitis
- GYN, GU, GI malignancy
- Ovarian retention syndrome
- IBD, IBS
- Constipation, celiac disease, diverticulosis
- Pelvic adhesions
- Fibromyalgia, myofascial syndromes
- Neurological disorders, depression, anxiety

omnia™ EDUCATION

Key Considerations for Patient Care Strategies

- Acute symptoms and problems patient is dealing with
 - Impacts on her quality of life and relationships
- Comorbidities
- Reproductive life plans
- Longer-term health consequences
- Patient preferences
- Expectation of patient: treatment vs cure



Women's Emerging Reliance on Social Media

- Social media increasingly becoming a health resource for people with complex or debilitating health conditions
- Reproductive health-related concerns make up 90% of social media health inquiries made by women
- Women with pain are almost twice as likely to use social media to understand or manage their GYN conditions
- Women with pain are almost twice as likely to trust the information they find on social media

Piszczek CC, et al. Am J Obstet Gynecol. 2021; Epub ahead of print.

Omnia[™] FDUCATION

Current Approaches

- Endometriosis is now a clinical diagnosis initially; a complete pelvic exam is needed
 - Surgery can be reserved for cases that do not respond to medical therapy, pelvic masses, and acute presentation
 - Other individualized indications
- Design therapies that address woman's current complaint but also bridge to long-term suppression to reduce risk of recurrences



Chapron C, et al. Nat Rev Endocrinol. 2019;15(11):666-682.

Imaging Studies

- Transvaginal ultrasound
 - Identify endometrioma (93% sensitive; 96% specification)
 - Addition of color flow Doppler studies may improve its otherwise limited value
 - 3D imaging holds some promise
- Transrectal ultrasound
 - Enables visualization of rectal regions, bowel wall infiltrates
- MRI



Kiesal L, et al. Climacteric. 2019;22(3):296-302.

Classic Medical Treatments of Endometriosis

- One of two effects desired
 - Pseudo-decidualization and atrophy of implants (pseudopregnancy)
 - Progestin-only therapies
 - Progestin-dominant combined hormonal therapy
 - Pseudo-menopause to suppress estrogen
 - Androgens
 - GnRH agonists
 - Aromatase inhibitors
- Combine with inhibition of inflammation and pain
 - NSAIDs, opioids

Omnia[™]

• Important point: these are all treatments, not cures

Combined Oral or Vaginal Contraceptives as First-Line Therapy

- Progestational effects are key to success
 - 2/3 of women have relief from pain and have improvement in QOL
- Continuous use superior to cyclic use¹
 - After surgery, less recurrence of:
 - Dysmenorrhea
 - Nonspecific pelvic pain
 - Endometrioma

omnia

FDUCATION

Progestin resistance can develop

1. Zorgas KA, et al. Arch Gynecol Obstet. 2015;292(1):37-43.

Combined Oral Contraceptives Lessons

- Cochrane insufficient evidence that treatment with COCs is superior to placebo¹
 - High degree of bias in studies
- Desogestrel in multiphasic pills as effective as GnRH analogues^{2,3}
- 25%-30% of women may have or develop progesterone resistance⁴



Brown J, et al. Cochrane Database Syst Rev. 2018;5(5):CD001019.
 Bedaiwy MA, et al. Fertil Steril. 2017;107(3):537-548.
 Granese R, et al. Acta Obstet Gynecol Scand. 2015;94(6):637-645.
 Vercellini P, et al. Fertil Steril. 2016;106(7):1552-1571.e2.

Progestin-Only Treatments

- Progestin-only pills may be better than combined therapies
- Dienogest 2 mg/day shrunk implants and reduced pain¹
 - Antiangiogenic properties important
- LNG-IUS 20 vs ENG implant²
 - 42.5% and 55.6% reduction in pain scores, respectively
- LNG IUS 20 effective in pain suppression following surgery³
- LNG IUS 20 vs depot GnRH analogue for CPP⁴



Carvalho N, et al. Fertil Steril. 2018;110(6):1129-1136.
 Andres MP, et al. Einstein (Sao Paulo). 2019;17(2):eAO4583.
 Song SY, et al. Eur J Obstet Gynecol Reprod Biol. 2018;231:85-92.
 Petta CA, et al. Hum Reprod. 2005;20(7):1993-1998.

Progestin-Only Treatments

- DMPA vs continuous COC postoperatively
 - DMPA reduced pain more¹
- SQ DMPA vs GnRH agonist
 - Equivalent symptom relief²
 - FDA-approved for treatment of pain symptoms of endometriosis



1. Cheewadhanaraks S, et al. Gynecol Obstet Invest. 2012;74(2):151-156. 2. Schlaff WD, et al. Fertil Steril. 2006;85(2):314-325.

Medical Therapies for Endometriosis Other

- Older treatments
 - GnRH agonists
 - Leuprolide depot, Goserelin, Nafarelin +/- add-back
 - Androgenic steroids
 - Danazol infrequently used due to side effects

- Emerging options
 - GnRH antagonists
 - Aromatase inhibitors (off-label)
 - Selective progesterone receptor modulators (not in USA)

Omnia[™] FDUCATION

Falcone T, et al. Obstet Gynecol. 2018;131(3):557-571.

Treatment of Endometriosis-Associated Pain: Elagolix

- In July 2018, the FDA approved elagolix as the first oral GnRH antagonist specifically developed for the treatment of moderate to severe pain associated with endometriosis.
- Supporting clinical trial data came from 2 similar double-blind studies:
 - Elaris EM-I (EM-I) and Elaris EM-II (EM-II)



Elagolix: EM-I and EM-II (Taylor and colleagues, 2017)

- Both randomized, 6-month, phase 3 trials in endometriosis
- Evaluated elagolix as:


omnia[®]

FDUCATION

- Low dose, 150 mg q.d.
- High dose, 200 mg BID
- 872 women were randomized in EM-I; 817 in EM-II, resulting in evaluation of 653 and 632 women, respectively
- Endpoints: clinical response to dysmenorrhea and nonmenstrual pelvic pain at 3 months
 - Endpoints also assessed at 6 months

Results from EM-I and EM-II





(1.3 - 2.3) (2.5 - 4.0)

<0.001 <0.001

Elagolix, 200 mg twice daily

(1.1-1.7) (1.2-1.8)

<0.001 <0.001

(1.0-1.6) (1.4-2.1)

0.008 <0.001


Placebo Elagolix, 150 mg once daily

(1.7 - 3.1) (2.9 - 4.9)

<0.001 <0.001

B Elaris EM-II

Two-sided P value



omnia[™] EDUCATION

Difference from placebo -21 52 13 11 22 21 50 21 (12-30) (41-58) (12-30) (43-60) % (97.5% CI) (4-23) (12-31) (1-21) (12-31) Risk ratio (97.5% CI) 1.9 3.2 1.8 3.1 1.4 1.6 1.3 1.5 (1.4-2.5) (2.5-4.0) (1.3-2.3) (2.4-3.8) (1.1-1.6) (1.3-1.9) (1.0-1.5) (1.2-1.8) Two-sided P value <0.001 <0.001 0.01 <0.001 <0.001 <0.001 0.003 < 0.001

Taylor HS, et al. N Engl J Med. 2017;377(1):28-40.

Elagolix 6-Month Endometriosis Extensions (EM-III and EM-IV)

- Evaluated efficacy and safety of elagolix over 12 months
 - An additional 6-month treatment for women in EM-I and EM-II phase 3 trials
- Same 2 elagolix doses tested: 150 mg q.d and 200 mg BID
- Endpoints: clinically meaningful pain reduction and nonmenstrual pelvic pain scores
 - Data on dyspareunia were also reported



Surrey E, et al. Obstet Gynecol. 2018;32(1):147-160.

EM-III and EM-IV Results: Proportion of Responders

	Elaris	EM-III	Elaris EM-IV		
Responders*	Elagolix 150 mg QD	Elagolix 200 mg BID	Elagolix 150 mg QD	Elagolix 200 mg BID	
Dysmenorrhea					
6 mo of treatment ⁺	60/149 (40.3)	109/136 (80.1)	72/142 (50.7)	107/140 (76.4)	
12 mo of treatment [*]	61/117 (52.1)	86/110 (78.2)	62/122 (50.8)	88/116 (75.9)	
Nonmenstrual pelvic pain					
6 mo of treatment ⁺	74/149 (49.7)	96/136 (70.6)	82/142 (57.7)	89/140 (63.6)	
12 mo of treatment [*]	79/117 (67.5)	76/110 (69.1)	81/122 (66.4)	78/116 (67.2)	
Dyspareunia					
6 mo of treatment ⁺	42/113 (37.2)	54/92 (58.7)	47/108 (43.5)	62/100 (62.0)	
12 mo of treatment [*]	38/84 (45.2)	42/70 (60.0)	39/85 (45.9)	43/74 (58.1)	

QD, once daily; BID, twice daily.

Data are n/N (%).

Between-group comparisons were not predefined and not performed. Data are observed, nonmissing data.

* Responders had a clinically meaningful reduction in the respective type of pain and stable or decreased rescue analgesic use.

⁺ Month 6 in the preceding double-blind, placebo-controlled trials; data are from women who enrolled in the extension studies.

⁺ After an additional 6 months of treatment in the extension study; some women received greater than 6 months of additional elagolix treatment while individual eligibility for extension study enrollment was assessed (see Materials and Methods).

omnia™ EDUCATION

Surrey E, et al. Obstet Gynecol. 2018;32(1):147-160.

Elagolix Impact on Non-Pain Symptoms in Endometriosis

- HRQoL was assessed using the 30-item Endometriosis Health Profile (EHP-30) score
- Assessed 5 core domains:
 - Pain (11 questions)
 - Control and powerlessness (6 questions)
 - Emotional well-being (6 questions)
 - Social support (4 questions)
 - Self-image (3 questions)
- Also added intercourse as the 6th domain (5 questions)
- Elagolix therapy over the 6-month period significantly reduced EHP-30 scores across all domains
- The higher 200-mg dose BID was more effective than the lower 150-mg dose q.d.

omnia™ EDUCATION

Relugolix: FDA Status for Endometriosis and ASRM 2021

- Relugolix, an oral GnRH antagonist, is currently under review at the FDA for the treatment of moderate to severe pain associated with endometriosis
- The NDA submission is based on data from SPIRIT 1 and SPIRIT 2 clinical trials, in addition to the phase 3 SPIRIT extension study
 - PDUFA date for relugolix is May 6, 2022

Omnia™ EDUCATION

- At ASRM, the effect of Rel-CT on health-related quality of life (QoL) was evaluated; 1,261 women were randomized 1:1:1 to once-daily Rel-CT, placebo, or delayed Rel-CT (relugolix 40 mg monotherapy then Rel-CT for 12 weeks each)
- With Rel-CT vs placebo, the proportions of dysmenorrhea and of NMPP responders were 74.9% vs 28.6% and 62.2% vs 41.1%, respectively (both P < 0.0001)

SPIRIT 1 and 2 Composite Findings at 24 Weeks: Presented at ASRM 2021 (EHP-30 Total Score Outcomes)

			Change from Bas	P value	
	Rel-CT (n = 411)	Placebo (n = 412)	Rel-CT (n = 343)	Placebo (n = 327)	(Rel-CT vs Placebo) at Week 24
Total Score	56.9 (0.9)	54.4 (0.9)	-29.9 (1.2)	-17.7 (1.2)	<0.0001
Pain	58.3 (0.9)	56.2 (0.9)	-33.0 (1.2)	-19.2 (1.2)	<0.0001
Emotional Well- Being	51.0 (1.2)	47.7 (1.2)	-23.3 (1.3)	-14.6 (1.3)	<0.0001
Control and Powerlessness	65.2 (1.2)	61.9 (1.2)	-37.4 (1.4)	-22.6 (1.4)	<0.0001
Self-Image	51.9 (1.4)	48.8 (1.4)	-23.3 (1.5)	-12.2 (1.5)	<0.0001
Social Support	54.0 (1.4)	52.6 (1.4)	-24.7 (1.4)	-15.3 (1.5)	<0.0001



Mathur V, et al. Presented at ASRM 2021: https://asrm.confex.com/asrm/2021/meetingapp.cgi/Paper/10852

Linzagolix Findings in Endometriosis (in Clinical Trials)

- Linzagolix is a GnRH antagonist being studied for the management of endometriosis pain
- The phase 2b EDELWEISS 1 study has been completed
- Evaluated 75, 100, and 200 mg doses for 24 weeks, with possible extension to 52 weeks
- At week 12, significant reductions were observed at ≥75 mg and maintained through to 52 weeks



Linzagolix Findings in Endometriosis (con't.)

- Pivotal phase 3 clinical trials have been initiated
- EDELWEISS 2 (US, since discontinued due to pandemic)
- EDELWEISS 3 (US and EU); anticipated completion 4Q 2021
 - Will enroll approx. 450 patients
 - Co-primary endpoints of reductions in dysmenorrhea/menstrual pain and nonmenstrual pelvic pain
 - Study includes patients receiving 200 mg linzagolix with or without add-back therapy
 - For patients completing the 6-month course, a 6-month extension study will be offered

omnia[™] EDUCATION

New Developments in Endometriosis

- New appreciation that this is a chronic, progressive inflammatory process that has systemic health impacts
- New understanding that adolescent and young women are frequently affected
 - Recognition that a delay in diagnosis of 7+ years persists
- New practice approaches for diagnosis are minimizing role of surgery
- New medical therapies to treat and suppress condition



Shared Decision-Making (SDM)

- Shared decision-making (SDM) is an approach in which <u>clinicians and patients communicate</u> using the best available evidence when making decisions
- Steps:
 - Introducing choice
 - <u>Describing options</u>, often by integrating the use of patient decision aids or support
 - Helping patients explore preferences and make collaborative decisions
- Components:
 - Understanding the risks associated with the condition
 - Understanding the options, including the benefits, risks, alternatives, and uncertainties
 - Weighing personal values regarding potential benefits and harms and respecting <u>"what</u> <u>matters most" to patients as individuals</u>
 - Participating in decision-making at the desired level

omnia™ EDUCATION

Sheridan SL, et al. Am J Prev Med. 2004;26(1):56-66. Elwyn G, et al. J Gen Intern Med. 2012;27(10):1361-1367.

Strategies for Endometriosis Care


General

Omnia[™] FDUCATION

- Listen to your patient attentively: goals, fears, experiences
- Develop relationship of trust and teamwork
- Use decision aids when appropriate
- Treatment risk and benefits
 - Explain goals of therapy
 - Personalize treatment selection
 - Management plans should consider
 - Symptom severity
 - Potential for recurrence
 - Desire for fertility
 - Other considerations: cost, side effects, route of administration
 - Describe risks that are common, including feared risks
 - Monitor for tolerance, compliance, persistence, and effectiveness

Consider Utilizing Tools to Regularly Reassess Pain

- At every visit, ask your patient specific questions about pain, other symptoms, and the impact on her life
 - One example of an assessment tool is the Endometriosis Pain and Impact Questionnaire



-						Concernance
	OL	01		Q4.	01	Disease
	D1		01	01		(Crew.pet)
	01				01	Greekants
	Ol	01	10			Dimente
	C)		27	100		Dimati
	C:	·		24		O'ren art
	Designation (21	C)				Orme anti-
0			24.3	1 01	CT .	Di Di Di U pendidari ri
0	keyarkta	e . 14.09	njinda		in Sergel	print reliate pro

ENDOMETROSS

ILAND IMPACT QUESTIONINUSE

205-1513024 25

Challenges in Shared Decision-Making

- Physicians typically spend less than 1 minute out of a 20-minute office visit discussing treatment and plans¹
- Average duration of an office visit is 7¹/₂ minutes²
- Informed decision-making occurs in only 9% of office visits²
- Physicians ask patients if they have questions in less than half of office visits²
- Patients recall only a fraction of the information presented^{3,4}



1. Waitzkin H. JAMA. 1984;252:2441-2446.

2. AbbVie Endometriosis Dialogue Survey 1/2017.

3. Braddock CH 3rd, et al. JAMA. 1999;282(24):2313-2320.

4. Lloyd AJ, et al. Lancet. 1999;353(9153):645.

Potential Benefits of Effective Risk Communication and Shared Decision-Making

- Patients have <u>better understanding</u> of:
 - Disease consequences
 - Benefits of therapy
 - Potential harms of therapy
- Reduced mistrust and fear
- Better collaboration between provider and patient; improved patient experience
- Improved adherence with therapy
- Improved health outcomes and quality of life
- Possible reduced costs

EndoSHARE



Stacey D, et. al. Cochrane Database Syst Rev. 2014;(1):CD001431. O'Connor AM, et al. Health Aff (Millwood). 2004;Suppl Variation:VAR63-72. Wilson SR, et al. Am J Respir Crit Care Med. 2010;181(6):566-577. Naik AD, et al. Circulation. 2008;117(11):1361-1368. Clever SL, et al. Med Care. 2006;44(5):398-405.

			BUCHENTROSS ACTION PUM Instrumentation of the instrument and the first sector that the instrument of the instrument instrument instrument Reserved	
			Bio (CHAPA	
	Recommended action plan	TRECOUT		
		5045	Justen Legun	
SAR	Stort ten Leep ten	CUMENT NOTWORKD MAAKDMENT		
		Appl. microsoft	and suggest	
r Honoco Ement		RUTURE MARANCHENT OFFICIES		
LPIENT		10,049		
statebo	end sucymot			
DHENT Ki	3	AND.	ter ly relevant	
HUP AL		Nobeliani Nob Conservatives Nobelianisti	Ber .	
		Neterenation	nak ni pasana ni paki maini ka mina makatan ka mina makata ya mini na disi katika mina. Mana kapanga mata pakana danan ka katika mina mata kati na Markata mata mata kati na Markata mana mina mina mi	

